PharmaTimes is the UK's leading pharmaceutical magazine, tracking the trends and issues that affect the industry here in the UK, in Europe and across the world. We deliver independent, authoritative and trustworthy content through impartial, balanced and informed opinion and analysis.
PharmaTimes print and digital versions have a total circulation of 23,184, reaching right across the industry into every company and every function. What's more, our circulation includes 8,000 NHS healthcare professionals: chief pharmacists, medicines management and primary care commissioners.
Despite the excitement surrounding T-cell therapy, CAR-T cells have fallen short in effectiveness against solid tumours. Oxfordshire-based Adaptimmune is one of the companies exploring T-cell receptors as a promising alternative. We spoke to the company’s chief technology officer Gwen Binder-Scholl about the science behind this challenging but exciting therapeutic area